Interaction of a selective serotonin reuptake inhibitor with insulin in the control of hepatic glucose uptake in conscious dogs

American Journal of Physiology - Endocrinology and Metabolism

Volumn 288, Issue 3 51-3, 2005, Pages

  Moore, Mary Courtney ^a   DiCostanzo, Catherine A ^a   Dardevet, Dominique ^a   Lautz, Margaret ^a   Farmer, Ben ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluvoxamine; Glycemia; Liver

Indexed keywords

CARBON; FLUVOXAMINE; GLUCAGON; GLUCOSE; INSULIN; RECOMBINANT GLUCAGON; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; SOMATOSTATIN; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL SPECIFICITY; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GLUCOSE TRANSPORT; GLYCOGEN LIVER LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; ISOTOPE LABELING; LIVER CELL; MALE; MOLECULAR INTERACTION; NONHUMAN; PORTAL VEIN; POSTPRANDIAL STATE; PRIORITY JOURNAL; REGULATORY MECHANISM;

ANIMALS; BLOOD FLOW VELOCITY; BLOOD GLUCOSE; CARBON; CONSCIOUSNESS; DOGS; DRUG INTERACTIONS; FATTY ACIDS, NONESTERIFIED; FEMALE; FLUVOXAMINE; GLUCAGON; GLUCOSE; GLYCEROL; GLYCOGEN; INFUSIONS, INTRAVENOUS; INSULIN; LACTIC ACID; LIVER; LIVER CIRCULATION; MALE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SOMATOSTATIN;

EID: 13844264118     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00405.2004     Document Type: Article

References (41)

1. Adeghate E, Ponery AS, Pallot D, Parvez SH, and Singh J. Distribution of serotonin and its effect on insulin and glucagon secretion in normal and diabetic pancreatic tissues in rat. Neuroendocrinol Lett 20: 315-322, 1999.
2. Adkins BA, Myers SR, Hendrick GK, Stevenson RW, Williams PE, and Cherrington AD. Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. J Clin Invest 79: 557-565, 1987.
3. Clerk LH, Smith ME, Rattigan S, and Clark MG, Nonnutritive flow impairs uptake of fatty acid by white muscles of the perfused rat hindlimb. Am J Physiol Endocrinol Metab 284: E611-E617, 2003.
4. Coulie B, Tack J, Bouillon R, Peeters T, and Janssens J. 5-Hydroxytryptamine-1 receptor activation inhibits endocrine pancreatic secretion in humans. Am J Physiol Endocrinol Metab 274: E317-E320, 1998.
5. Cowan JS and Hetenyi G Jr. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 20: 360-372, 1971.
6. Galassetti P, Shiota M, Zinker BA, Wasserman DH, and Cherrington AD. A negative arterial-portal vein glucose gradient decreases skeletal muscle glucose uptake in the conscious dog. Am J Physiol Endocrinol Metab 275: E101-E111, 1998.
7. Gustavson SM, Chu CA, Nishizawa M, Farmer B, Neal D, Yang Y, Donahue EP, Flakoll P, and Cherrington AD. Interaction of glucagon and epinephrine in the control of hepatic glucose production in the conscious dog. Am J Physiol Endocrinol Metab 284: E695-E707, 2003.
8. Hendrick GK, Frizzell RT, Williams PE, and Cherrington AD. Effect of hyperglucagonemia on hepatic glycogenolysis and gluconeogenesis after a prolonged fast. Am J Physiol Endocrinol Metab 258: E841-E849, 1990.
9. Holste LC, Connolly CC, Moore MC, Neal DW, and Cherrington AD. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol Endocrinol Metab 273: E488-E496, 1997.
10. Hoyer D, Hannon JP, and Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71: 533-554, 2002.
11. Hsieh PS, Moore MC, Neal DW, Emshwiller M, and Cherrington AD. Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Am J Physiol Endocrinol Metab 276: E930-E937, 1999.
12. Hsieh PS, Moore MC, Neal DW, Venson P, and Cherrington AD. Hepatic glucose uptake rapidly decreases after elimination of the portal signal in conscious dogs. Am J Physiol Endocrinol Metab 275: E987-E992, 1998.
13. Ikejima K, Lang T, Zhang YJ, Yamashina S, Honda H, Yoshikawa M, Hirose M, Enomoto N, Kitamura T, Takei Y, and Sato N. Expression of leptin receptors in hepatic sinusoidal cells. Comp Hepatol 3, Suppl 1: S12, 2004.
14. Keppler D and Decker K. Glycogen: determination with amyloglucosidase. In: Methods in Enzymatic Analysis, edited by Bergmeyer HU. New York: Verlag Chemie Weinheim-Academic, 1974, p. 1127-1131.
15. Lam NT, Lewis JT, Cheung AT, Luk CT, Tse J, Wang J, Bryer-Ash M, Kolls JK, and Kieffer TJ. Leptin increases hepatic insulin sensitivity and protein tyrosine phosphatase 1B expression. Mol Endocrinol 18: 1333-1345, 2004.
16. Li T, Leng XS, Weng SG, Peng JR, Wei YH, Mou DC, Wang WX, and Zhu JY. Expression of 5-hydroxytamine receptors in hepatic stellate cell and action of 5-hydroxytamine on biological characteristics of hepatic stellate cell. Zhonghua Wai Ke Za Zhi 41: 175-179, 2003.
17. Marco J, Hedo JA, Martinell J, Calle C, and Villanueva ML. Potentiation of glucagon secretion by serotonin antagonists in man. J Clin Endocrinol Metab 42: 215-221, 1976.
18. McGuinness OP, Fugiwara T, Murrell S, Bracy D, Neal D, O'Connor D, and Cherrington AD. Impact of chronic stress hormone infusion on hepatic carbohydrate metabolism in the conscious dog. Am J Physiol Endocrinol Metab 265: E314-E322, 1993.
19. Moore MC, Cherrington AD, Cline G, Pagliassotti MJ, Jones EM, Neal DW, Badet C, and Shulman GI. Sources of carbon for hepatic glycogen synthesis in the conscious dog. J Clin Invest 88: 578-587, 1991.
20. Moore MC, DiCostanzo CA, Dardevet D, Lautz M, Farmer B, Neal DW, and Cherrington AD. Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs. Am J Physiol Endocrinol Metab 287: E1057-E1063, 2004.
21. Moore MC, Flakoll PJ, Hsieh PS, Pagliassotti MJ, Neal DW, Monohan MT, Venable C, and Cherrington AD. Hepatic glucose disposition during concomitant portal glucose and amino acid infusions in the dog. Am J Physiol Endocrinol Metab 274: E893-E902, 1998.
22. Moore MC, Geho WB, Lautz M, Farmer B, Neal DW, and Cherrington AD. Portal serotonin infusion and glucose disposal in conscious dogs. Diabetes 53: 14-20, 2004.
23. Moore MC, Hsieh PS, Neal DW, and Cherrington AD. Nonhepatic response to portal glucose delivery in conscious dogs. Am J Physiol Endocrinol Metab 279: E1271-E1277, 2000.
24. Moore MC, Pagliassotti MJ, Wasserman DH, Goldstein R, Asher J, Neal DW, and Cherrington AD. Hepatic denervation alters the transition from the fed to the food-deprived state in conscious dogs. J Nutr 123: 1739-1746, 1993.
25. Myers SR, Biggers DW, Neal DW, and Cherrington AD. Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. J Clin Invest 88: 158-167, 1991.
26. Nathan C and Rolland Y. Pharmacological treatments that affect CNS activity: serotonin. Ann NY Acad Sci 499: 277-296, 1987.
27. Nishizawa M, Moore MC, Shiota M, Gustavson SM, Snead WL, Neal DW, and Cherrington AD. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol Endocrinol Metab 284: E1027-E1036, 2003.
28. Otte C, Otte JM, Strodthoff D, Bornstein SR, Folsch UR, Monig H, and Kloehn S. Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes 112: 10-17, 2004.
29. Pagliassotti MJ, Holste LC, Moore MC, Neal DW, and Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the dog. J Clin Invest 97: 81-91, 1996.
30. Pussard E, Guigueno N, Adam O, and Giudicelli JF. Validation of HPLC-amperometric detection to measure serotonin in plasma, platelets, whole blood, and urine. Clin Chem 42: 1086-1091, 1996.
31. Rattigan S, Dora KA, Colquhoun EQ, and Clark MG. Serotonin-mediated acute insulin resistance in the perfused rat hindlimb but not in incubated muscle: a role for the vascular system. Life Sci 53: 1545-1555, 1993.
32. Rothman DL, Magnusson I, Katz LD, Shulman RG, and Shulman GI. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254: 573-576, 1991.
33. Satake S, Moore MC, Igawa K, Converse M, Farmer B, Neal DW, and Cherrington AD. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes 51: 1663-1671, 2002.
34. Steele R, Wall JS, DeBodo RC, and Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1956.
35. Tatsumi M, Groshan K, Blakely RD, and Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258, 1997.
36. Uvnas-Moberg K, Ahlenius S, Alster P, and Hillegaart V. Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat. Neuroendocrinology 63: 269-274, 1996.
37. Van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29: 1-9, 1995.
38. Yamada J, Sugimoto Y, and Ujikawa M. Effects of insulin and adrenalectomy on elevation of serum leptin levels induced by 5-hydroxytryptophan in mice. Biol Pharm Bull 26: 1491-1493, 2003.
39. Yamada J, Sugimoto Y, and Ujikawa M. The serotonin precursor 5-hydroxytryptophan elevates serum leptin levels in mice. Eur J Pharmacol 383: 49-51, 1999.
40. Yamada J, Sugimoto Y, Ujikawa M, Goko H, and Yagura T. Hyperleptinemia elicited by the 5-HT precursor, 5-hydroxytryptophan in mice: involvement of insulin. Life Sci 73: 2335-2344, 2003.
41. Yamada J, Ujikawa M, and Sugimoto Y. Serum leptin levels after central and systemic injection of a serotonin precursor, 5-hydroxytryptophan, in mice. Eur J Pharmacol 406: 159-162, 2000.